<DOC>
	<DOCNO>NCT01224366</DOCNO>
	<brief_summary>To assess efficacy safety vildagliptin add-on therapy reduce HbA1c patient T2DM inadequately control insulin , without concurrent metformin therapy .</brief_summary>
	<brief_title>Efficacy Safety Vildagliptin add-on Therapy Insulin Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Confirmed diagnosis T2DM On stable dose insulin define protocol On stable metformin ( applicable ) define protocol Age 18 80 year HbA1c 7.5 11.0 % Body Mass Index ( BMI ) 22 40 kg/m2 Type 1 diabetes Shortacting rapidacting insulin Pregnancy lactation Evidence serious diabetic complication Evidence serious cardiovascular complication Laboratory value abnormality define protocol Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Add-on insulin</keyword>
</DOC>